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Abstract 
Background: To find out the association of 
circulating serum leptin levels with metabolic 
syndrome. 
Methods: This case-control study was conducted 
on 100 adult subjects (consisting  of  50 cases  who  
fulfiled the WHO criteria of metabolic syndrome 
(Mets) along with equal number of age and sex 
matched controls). Enzymatic colorimetric method 
was used to measure fasting plasma glucose and 
lipid profile. Insulin resistance was calculated by 
using the Homeostasis Model Assessment-Insulin 
Resistance (HOMA-IR). Circulating leptin levels 
were measured using DRG Leptin (Sandwich) 
ELISA kit. Statistical Package for the Social Sciences 
(SPSS)-17 was used to analysis of data. 
Results: The Mets group comprised of 59% subjects 
with IFT, 25% with impaired glucose tolerance 
(IGT), while 16% were diabetic. Mets patients were 
more obese, as represented by increased BMI, WC 
and WHR.  Dyslipidemia along with elevated levels 
of fasting plasma glucose and fasting plasma insulin 
were observed in case group as measured by HOMA-
IR. Patients with Mets had elevated leptin levels of 
12.98 ± 2.68 (ng/ml) as compared to 5.34 ± 1.84 (ng/ml) 
in controls (p value < 0.001). 
Conclusion: Serum leptin levels were significantly 
raised in subjects of Metabolic syndrome as 
compared to controls. Early detection of metabolic 
syndrome patients by measuring their circulating 
serum levels will be helpful in reducting the risk of 
various cardio-metabolic abnormalities (diabetes 
melitus and cardiovascular diseases) which  are 
associated with this syndrome. 
 Key words: Serum leptin, Metabolic syndrome, 
Insulin resistance, Body-mass index, Homeostasis 
Model Assessment-Insulin Resistance (HOMA-IR). 
 
Introduction 
    Metabolic syndrome (Mets) also known as “Multiple 
Risk Factor Clustering syndrome”  is a combination of 
hyperglycaemia,  hyperinsulinaemia,  hypertension 
and dyslipidaemia in an individual.1 Study done in 
2009 estimated the prevalence of Mets in Karachi and 
gave the figure of  approximately 35% according to 
International Diabetes Federation (IDF) definition and 
modified National Cholesterol Education Program, 
however the figure was 49% when Adult Treatment 
Panel III (NCEP ATP III) criteria was used.2 The 
increased trend towards Mets was attributed due to 
high prevalence of obesity (46-68%) and lower levels 
of  HDL-c (68-81%).3 High prevalence of CVD and DM 
 has also been observed in Pakistani population as 
well.4  
 The cause of Mets is a mixture of genetic and 
environmental factors.5 It helps in assessing risk for 
developing serious complications. Data shows that 
Mets not only increases the risk of coronary artery 
disease and DM but also cerebrovascular diseases in 
Asia.6 The hallmark of Mets is, indeed obesity, which 
is an epidemic of 21st century. It is a chronic condition, 
which is continuing to plague our society.7 Although 
prevalence of obesity is relatively low in Asia as 
compared to the developed countries, it is growing 
into a significant public health problem.6 General 
population has 17% to 25% prevalence of Mets, giving 
the strong evidence of interconnected link between 
obesity and Mets.8 Obesity is considered as the 
underlying cause of this rising pandemic.9 
 Apart from inflammatory cytokines like TNF-alpha 
and IL-6, adipose tissue secretes several adipokines 
(leptin, adiponectin and resistin). Some of these, affects 
insulin sensitivity by acting on insulin signaling and 
molecules involved in glucose metabolism.1 An 
elevated circulating levels of leptin has been found in 
obese individuals but they do not adequately 
respond to these increased leptin levels. This under-
responsiveness to either endogenous and exogenous 
leptin in most forms of obesity has given rise to the 
idea that obesity is associated with or even caused by a 
state of relative leptin resistance similar to the insulin 
resistance of type 2 diabetes.10 Elevated serum leptin 
concentration is a feature of obesity and abdominal 
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adiposity is a cardinal feature of Mets.11    As the 
number of people suffering from this syndrome is 
increasing day by day, their early diagnosis  will 
reduce the risk for developing Coronary heart disease 
(CHD), peripheral vascular diseases, stroke and type 
2-DM.12 Hence, Mets identifies these individuals 
towards whom preventive medicine should be 
targeted.13 
 
Patients and Methods 
 After getting permission from the Institutional Ethics 
Committee of Army Medical College, this case control 
study was done on 100 subjects. Each participant gave 
the written consent. To diagnose the metabolic 
syndrome patient, WHO criteria was used; which is 
based on insulin resistance (IR) plus any 2 of 
following: (i) BMI>25 kg/m2 or waist-hip ratio>0.85 in 
women and >0.9in men; (ii) High blood 
pressure≥140mm Hg systolic or ≥90 mm Hg diastolic; 
(iii) Serum Triglyceride≥1.7mmol/l; (iv)Serum HDL 
cholesterol<1.0 in women and<0.9 in men. Regarding 
cases, patients with a history of liver, thyroid, 
hematological and neoplastic diseases were  excluded, 
while in controls, pregnant women and those who 
were taking oral contraceptive pills were excluded. 
Information regarding the demographic data (age, sex 
etc) and complete history was  obtained.  
Anthropometric indices of obesity included ,waist and 
hip circumference were measured in centimeters for 
calculating waist-to-hip ratio. Waist circumference was 
measured midway between the iliac crest and the 
lower margin of the 12th rib and height was measured 
to the nearest cm with a standardized measuring chart 
and weight was measured to the nearest kg with a 
standardized scale without shoes. BMI was calculated 
by the formula=Weight (kg)/Height(m2). 
Ten ml of fasting venous blood sample was  collected 
under sterile conditions and equal amounts was 
transferred to a plain vacutainer for serum analysis 
and EDTA tube for plasma analysis.Serum was 
separated by centrifugation for 15 minutess. Routine 
investigations was done on the same day.The serum 
for leptin and insulin measurements was stored at -20 
0C , until  the biochemical analysis.Plasma glucose, 
triglyceride, total cholesterol and high density 
cholesterol (HDL-c) were measured by the enzymatic 
colorimetric method on fully automated chemistry 
analyzer . Low density cholesterol(LDL-c)  was 
calculated by Friedewald formula , i.e.,  LDL-
c(mmol/l)= [TC]-[HDL-TG/2.2] 
Serum Leptin was measured in Mets patients by using 
DRG Leptin- ELISA (enzyme-linked immunosorbent 
assay) kit for research use only. Insulin was  measured 
on Access- 2 immunoassay (Beckman Coulter) based 
on principle of chemiluminance immunoassay. 
Homeostasis Model Assessment-Insulin Resistance 
(HOMA-IR) was used to measure Insulin resistance, 
i.e., Homa-IR=fasting plasma glucose × fasting plasma 
insulin/22.5 . Categorical data was compared using 
the chi-square test. Serum Leptin levels in the groups 
were compared using independent t-test. Correlation 
analysis of serum Leptin with the Mets components 
was done using Spearman correlation. A p-value < 
0·05 was considered to indicate statistical significance. 
Results 
One hundred patients of Mets  with an equal 
number of age and sex matched controls were 
included in this study. Among the 50 Mets patients, 
28 (56%) were male and 22 (44%) were female . Out 
of 50 subjects of control group, 26 (52%) were male 
and 24 (48%) were female. Mean age of the cases and 
control  was 45.24 ± 7.99 and 44.30 ± 7.88  years 
respectively. The Mets group comprised of 59% 
subjects with IFT, 25% with IGT, while 16% diabetic. 
 
Table 1: The baseline characteristics of the cases 
and controls 
Parameters    Cases 
(Mean & SD)  
    Controls 
(Mean  &SD) 
  p-value 
Age (yrs)    45.24 ± 7.99 44.30 ± 7.88 0.555 
Basal metabolic rate 
(BMI,unit: kg/m2) 
29.40 ± 1.49 22.71 ± 1.04 < 0.001 
Waist circumference 
(WC,unit: cm) 
51.72 ± 7.12 36.20 ± 2.39 < 0.001 
Waist hip ratio 
(WHR) 
  1.125 ± 
0.081 
 0.786 ± 0.022 < 0.001 
Fasting plasma 
Glucose (mmol/l) 
 6.94 ± 0.759 4.27 ± 0.608 < 0.001 
Fasting plasma 
Insulin (µIU/ml) 
28.39 ± 1.67 11.85 ± 1.14 < 0.001 
HOMA-IR       79 ± 1.47  2.22 ± 0.196 < 0.001 
Serum Triglyceride  
(TG, unit: mmol/l) 
  4.09 ± 1.42  1.03 ± 0.292 < 0.001 
Plasma High density 
lipoprotein 
cholesterol 
(HDL,unit: mmol/l) 
 
   0.779 ± 
0.090 
 
 2.48 ± 0.372 
 
< 0.001 
Serum Leptin 
(ng/ml) 
 
12.98 ± 2.68 
 
5.34± 1.84 
 
< 0.001 
 
Mets patients were more obese, as represented by 
increased BMI, WC and WHR.  Moreover,  
dyslipidemia  with elevated levels of serum TG, 
decreased levels of plasma HDL-c were seen in these  
patients.   Elevated levels of fasting plasma glucose 
and fasting plasma insulin were observed in case 
group as measured by HOMA-IR. However, no 
significant difference was observed in BP readings of 
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the case and control groups. We have observed a  
significant difference in serum leptin levels  among 
cases and controls. Patients with Mets had elevated 
leptin levels of 12.98 ± 2.68 (ng/ml) as compared to 
5.34 ± 1.84 (ng/ml) in controls (p value < 0.001) (Table 
1). 
Discussion 
 Studies found raised serum leptin levels in Mets 
subjects.14,15,16 Insulin resistance which is a  well  
recognized risk factor for the development of type-2 
diabetes and cardiovascular diseases had been clearly 
demonstrated in metabolic syndrome patients.17-19 
Previously there was controversy about the 
relationship between leptin and insulin resistance. In 
obese individuals, both the serum leptin and insulin 
levels are generally high, but some studies showed an 
inverse relation between   serum leptin level and 
insulin resistance. In this way,  the relationship 
between  leptin and insulin resistance was less clear.20 
Associations of serum leptin and insulin levels have 
been reported in subjects with or without insulin 
resistance e.g. study showed an increase in serum 
leptin levels after  insulin infusion.21 Study done by 
Boden et al.,  established a dose-dependent  increase in 
serum leptin levels during 72 hours of 
hyperinsulinemia.22,23 This suggests that  prolonged 
hyperinsulinemia  enhances leptin expression in 
humans. However, Vidal et al. failed to increase leptin 
mRNA in human adipose tissues.24  
This study was done by calculating the  insulin 
resistance by using HOMA-IR equation  as it is easy, 
manageable and is commonly used for population 
based studies.25,26 In a study conducted by Julia 
Steinberger et al., the euglycaemic-hyperinsulinaemic 
glucose clamp technique  was used which is 
considered the gold standard for evaluating insulin 
sensitivity.27 The above technique is usually not 
preferable as it needs admission in hospital and there 
is a risk of hypoglycemia and prolonged time duration 
of procedure i.e three to four hours.28 This is basis for 
using  HOMA-IR for present study as it is  less 
invasive and easy to use, moreover, the values of  
insulin resistance obtained from euglycaemic-
hyperinsulinaemic glucose clamp technique were 
comparable to our study. Toshio et al. have compared 
HOMA with clamping technique, and found good 
correlation.29  A cut off  value of  2.5 in Mets patients 
was used for insulin resistance index , while in various 
other studies the range varies between 1.73- 2.5.30,31 
There is no universally agreed upon cut off value for 
HOMA-IR.19,28  Though variations exist  in the cut off 
values of HOMA  due to variability of insulin assay 
procedures, however, it has good utility as a research 
tool in population-based studies.31 Many studies used 
HOMA to determine insulin resistance in their 
population.32  Shimomura et al. suggested upper limit 
of HOMA-IR in Japanese subjects.33 In another study 
done on obese Type 2 diabetic  subjects  in Pakistan, 
mean value of HOMA-IR was 4.1 that may be due to 
diabetes mellitus in such patients.34 
 In present study,  serum leptin levels were measured 
by Sandwich ELISA technique. Serum leptin levels 
were also measured by using radioimmuno-assay 
technique.  Infact, Sandwich ELISA technique  is  
better than the radioimmuno-assay  as it is more 
specific because there are relatively much less chance 
of cross-reactivity to other biological products of 
human origin (cross-reactivity with mice leptin is 0.2% 
which is negligible).  There is no risk of radiations as in 
radioimmuno-assay.35  Also in study when  leptin was 
measured by RIA, the mean ± SD serum leptin 
concentrations were 31.3 ± 24.1 ng/ml in the obese 
subjects and 9.3 ± 7.5 ng/ml in the normal-weight 
subjects (P=0.001). In our study, these levels were 
12.98 ± 2.68 (ng/ml)  in the obese subjects and 5.34± 
1.84 (ng/ml)  in the normal-weight subjects. The leptin 
concentration is relatively low in obese group in 
present study which may be due to different method 
of analysis and/or study population.20 (Considine et 
al., 1996). 
 Metabolic syndrome represents a high risk population 
with multiple cardiometabolic risk factors, therefore, 
targeting this high risk group for primary prevention 
will greatly benefit the community both in terms of 
improvement in health and cost spend on treating 
diabetes and CVD.36,37  
 
Conclusion 
1. Serum leptin  levels were significantly raised in 
subjects of Metabolic syndrome as compared to 
controls.  
2. As leptin is secreted mainly by adipocytes in obese 
individuals, early diagnosis of these patients will 
be helpful in planning the intervention and 
therapeutic strategies to reduce the frequency of 
DM and CVDs. 
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